Spring Bank Pharmaceuticals (NASDAQ:SBPH) named Scott Smith as an independent member of the board, replacing Jonathan Bates, who is stepping down as a director after 10 years of service with the company.
Mr. Smith most recently was president and COO of Celgene (NAASDAQ:CELG), including a stint from 2010 through 2017, when he served as president of inflammation and immunology at Celgene. Mr. Smith also is on the board of Titan Pharmaceuticals (NASDAQ:TTNP) and closely-held Triumvira Immunologics.
In a statement, Martin Driscoll, chairman and CEO of Spring Bank, said Mr. Smith’s impressive career, involving the development of successful biopharmaceutical franchises and his deep experience and expertise drawn from his establishment of the industry-leading inflammation and immunology business at Celgene, will benefit Spring Bank as “we continue to progress our novel immunomodulatory compounds in chronic hepatitis B and immune-oncology.”
